No Data
No Data
Zhendong Pharmaceutical (300158.SZ) appoints Liu Yongsen as financial director
Zhendong Pharmaceutical (300158.SZ) announced that the company's board of directors recently received the written resignation of Liu Changlu, the company's financial director...
Zhendong Pharmaceutical (300158.SZ): Net profit of 23.1016 million yuan for the first quarter reversed year-on-year losses
Gelonghui, April 22 | Zhendong Pharmaceutical (300158.SZ) released its report for the first quarter of 2024. Operating revenue for the reporting period was 782 million yuan, down 17.79% year on year; net profit attributable to shareholders of listed companies was 23.1016 million yuan, turning a year-on-year loss into a profit; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss - 8.5924 million yuan; basic earnings per share.
Zhendong Pharmaceutical (300158.SZ) elects director Li Kun as chairman
Zhendong Pharmaceutical (300158.SZ) announced that the company's board of directors recently received a written resignation report from the company's chairman Li Anping...
Several major problems with equity pledges and capital occupation of Zhendong Pharmaceutical have come to light
“Investor Network” Cai Jun Recently, Zhendong Pharmaceutical (hereinafter referred to as the “Company”, 300158.SZ) announced that shareholders pledged shares, involving both the controlling party and the actual controller. Earlier, the company owned Landy Pharmaceuticals and relied on it to obtain a double harvest of capital and performance. However, since 2022, the company has been in losses, and when to turn losses into profits has become a topic of concern for the market. If you want to make a profit, you need revenue side growth and cost segment control. At the same time, various transactions between the holding party and the company have also received attention from the supervisory authorities. According to the announcement, Zhendong Group, the controlling shareholder of the company, and Li Anping, the actual controller, pledged a total of 305 million shares, accounting for the public
Zhendong Pharmaceutical (300158.SZ): A total cost of 46.72 million yuan to buy back 1.02% of the shares
Gelonghui, Feb. 23 | Zhendong Pharmaceutical (300158.SZ) announced that as of February 21, 2024, the company had repurchased a total of 10,497,004 shares of the company through a special stock repurchase securities account, accounting for 1.02% of the company's total share capital. The highest transaction price was 4.81 yuan/share, the minimum transaction price was 4.31 yuan/share, and the total transaction amount was RMB 46,724,627.55.
Zhendong Pharmaceutical (300158.SZ): Initial repurchase of 8.6463 million shares involving 38.675 million yuan
Gelonghui, Feb. 7, Zhendong Pharmaceutical (300158.SZ) announced that on February 7, 2024, for the first time, the company repurchased 86463.04 million shares through a special stock repurchase securities account, accounting for 0.84% of the company's total share capital. The highest transaction price was 4.54 yuan/share, the lowest transaction price was 4.31 yuan/share, and the total transaction amount was RMB 38.27,500 (not including transaction fees).
No Data